Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

Acta Oncologica

Volumn 50, Issue 4, 2011, Pages 569-573

  Bono, Petri ^a,b   Rautiola, Juhana ^a   Utriainen, Tapio ^a   Joensuu, Heikki ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB; THYROTROPIN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPERTHYROIDISM; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; FEMALE; HUMANS; HYPERTENSION; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PYRROLES; RISK FACTORS;

EID: 79955623124     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.543696     Document Type: Article

References (13)

1. Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of sunitinib activity. Ann Oncol 2007;18:1117. (Pubitemid 47050505)
2. Rini BI, Schiller JH, Fruehauf J, Cohen EE, Tarazi JC, Rosbrook B, et al. Association of diastolic blood pressure - 90 mmHg with overall survival in patients treated with axitinib. J Clin Oncol 2008;26(18S):3543.
3. Ravaud A, Sire M. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and secondline treatment of metastatic renal cell cancer. Ann Oncol 2009;20:966-7.
4. Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009;20:393-4.
5. Rini BI, Cohen DP, Lu D, Chen I, Hariharan S, Gore ME. Hypertension (HTN) as a biomarker of efficacy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. ASCO GU meeting 2010; Abstr 312.
6. van Heeckeren WJ, Ortiz J, Cooney MM, Remick SC. Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: Clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 2007;25: 2993-5. (Pubitemid 47218042)
7. Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-75.
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L. Guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
9. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010;70: 1063-71.
10. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24:217-27. (Pubitemid 46622051)
11. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005;97:981-9. (Pubitemid 41430564)
12. Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin Cancer Res 2009;15:5297-302.
13. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370: 2011-9. (Pubitemid 350236338)